Xtant Medical Holdings, Inc. (XTNT)
| Market Cap | 53.87M -32.3% |
| Revenue (ttm) | 109.53M -14.3% |
| Net Income | -11.14M |
| EPS | -0.08 |
| Shares Out | 140.29M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 77,602,132 |
| Open | 0.3452 |
| Previous Close | 0.3300 |
| Day's Range | 0.3397 - 0.4861 |
| 52-Week Range | 0.2702 - 0.9500 |
| Beta | -0.14 |
| Analysts | Buy |
| Price Target | 1.05 (+173.44%) |
| Earnings Date | Aug 11, 2026 |
About XTNT
Xtant Medical Holdings, Inc. provides regenerative medicine products and medical devices for orthopedic and neurological surgeons in the United States and internationally. It offers OsteoSponge, a natural scaffold for cellular in-growth; OsteoSelect DBM Putty, a moldable demineralized bone matrix; OsteoSelect PLUS DBM Putty to deliver handling properties and ensure patient safety through validated and terminal sterilization; 3Demin, a family of allografts that maximizes osteoconductivity and the osteoinductive potential of human bone; OsteoFact... [Read more]
Financial Performance
Financial StatementsAnalyst Summary
According to 2 analysts, the average rating for XTNT stock is "Buy." The 12-month stock price target is $1.05, which is an increase of 173.44% from the latest price.
News
Xtant Medical announces exclusive partnership with BioHorizons
Xtant Medical (XTNT) announced an exclusive partnership with BioHorizons, whereby BioHorizons will distribute Xtant’s allogeneic growth factor technology under the private brand Prolifica through its ...
Xtant Medical Announces Exclusive Partnership with BioHorizons to Expand Access to Xtant's Allogeneic Growth Factor into the Dental Market
Partnership leverages BioHorizons' commercial network to broaden availability of Xtant's allogeneic growth factor technology, OsteoFactor Pro™, which BioHorizons will private brand as Prolifica™ BELGR...
Xtant Medical Holdings Transcript: Canaccord Genuity's 46th Annual Growth Conference
Targeting major growth in orthobiologics and hemostasis, the company expanded its sales force and product lines, divested non-core assets, and expects to generate cash by Q4. Recent acquisitions and innovation support a diversified, high-margin portfolio.
Xtant Medical Holdings Earnings Call Transcript: Q2 2026
Q2 2026 revenue declined year-over-year due to asset sales and amnio headwinds, with gross margin and profitability also down. Expanded sales force and new products like HEMOBLAST and Trivium Shaped are expected to drive growth in the second half, though full-year guidance was modestly reduced.
Xtant Medical Holdings Earnings release: Q2 2026
Xtant Medical Holdings released its Q2 2026 earnings on August 11, 2026, summarizing the period's financial results.
Xtant Medical Holdings Quarterly report: Q2 2026
Xtant Medical Holdings has published its Q2 2026 quarterly earnings report on August 11, 2026.
Xtant Medical Holdings Slides: Investor presentation
Xtant Medical Holdings has posted slides in relation to its latest quarterly earnings report, which was published on August 11, 2026.
Xtant Medical Reports Second Quarter 2026 Financial Results
Launched Trivium™ Shaped, an extension of its Trivium line of premium, next-generation demineralized bone matrix allograft for bone grafting procedures Company to host investor conference call and web...
Xtant Medical to Announce Second Quarter 2026 Financial Results on August 11, 2026
BELGRADE, Mont., Aug. 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions,...
Xtant Medical to Participate in the Canaccord Genuity 46th Annual Growth Conference
BELGRADE, Mont., Aug. 4, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions,...
Xtant Medical Holdings Proxy statement: Proxy filing
Xtant Medical Holdings filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
Xtant Medical Holdings Proxy statement: Proxy filing
Xtant Medical Holdings filed a proxy statement on June 23, 2026, providing details for shareholder voting and corporate governance matters.
Xtant Medical reports Q1 EPS (2c) vs. 0c last year
Reports Q1 revenue $20.9M vs. $32.9M last year. Sean Browne, President and CEO of Xtant Medical (XTNT), stated, “The Q1 of 2026 and subsequent period were pivotal for Xtant. Proceeds…
Xtant Medical Holdings Earnings Call Transcript: Q1 2026
Q1 2026 revenue was $20.9M, with a net loss of $3.1M, reflecting divestitures and market headwinds. Full-year revenue guidance was raised to $101M–$105M, driven by new product launches and expanded sales force, with gross margin expected to recover in the second half.
Xtant Medical Holdings Earnings release: Q1 2026
Xtant Medical Holdings released its Q1 2026 earnings on May 13, 2026, summarizing the period's financial results.
Xtant Medical Holdings Quarterly report: Q1 2026
Xtant Medical Holdings has published its Q1 2026 quarterly earnings report on May 13, 2026.
Xtant Medical Reports First Quarter 2026 Financial Results
Raises full-year 2026 revenue guidance to a range of $101-$105 million Significantly strengthens balance sheet Enters into exclusive U.S. distribution agreement for Dilon Technologies' HEMOBLAST® Bell...
Xtant Medical to Announce First Quarter 2026 Financial Results on May 13, 2026
BELGRADE, Mont., May 7, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, ...
Xtant Medical Expands Trivium™ Portfolio with the Commercial Launch of Trivium™ Shaped
BELGRADE, Mont., May 6, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), a medical technology company focused on surgical solutions for spinal and other orthopedic conditions, ...
Xtant Medical resumed with a Buy at Maxim
Maxim resumed coverage of Xtant Medical (XTNT) with a Buy rating and $1.50 price target With the overall focus on the higher-growth and higher-margin orthobiologics business, Xtant is positioned for…
Xtant Medical acquires U.S. distribution rights to Dilon’s Hemoblast Bellows
Xtant Medical (XTNT) Holdings and Dilon Technologies announced that the companies have entered into an agreement whereby Xtant has acquired exclusive U.S. distribution rights to Dilon’s Hemoblast Bell...
Xtant Medical and Dilon Technologies Announce Exclusive U.S. Distribution Agreement for Dilon's HEMOBLAST® Bellows Product
Xtant has hired Dilon's U.S. sales team to assist in selling the HEMOBLAST ® Bellows product and penetrating the estimated $2.0 billion global addressable market for hemostatic products BELGRADE, Mont...
Xtant Medical and Montana Governor's Office of Community Service Announce Support for "Threshold of Life" Memorial
BELGRADE, Mont., April 9, 2026 /PRNewswire/ -- Xtant Medical Holdings, Inc. (NYSE American: XTNT), in partnership with the Montana Governor's Office of Community Service (GOCS), today announced suppor...
Xtant Medical Holdings Slides: Investor presentation
Xtant Medical Holdings has posted slides in relation to its latest quarterly earnings report, which was published on April 6, 2026.
Xtant Medical Holdings Earnings Call Transcript: Q4 2025
Revenue grew 14% in 2025 to $133.9M, with strong gross margin and a return to profitability. 2026 guidance reflects divestitures and non-recurring revenue loss, but core biologics is expected to accelerate as new products and expanded sales force drive growth.